PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10475144-8	1999	RESULTS: DTZ decreased resting DBP from 84 +/- 13 to 79 +/- 10 mmHg (p > 0.05), and HR from 89 +/- 11 to 82 +/- 13 bpm (p < 0.05).	Diltiazem	9-12	D-box binding PAR bZIP transcription factor	Homo sapiens	31-34	
10475144-10	1999	DTZ limited these increases to 21% for SBP, 5% for DBP, and 44% for HR (p < 0.05 for drug effect).	Diltiazem	0-3	D-box binding PAR bZIP transcription factor	Homo sapiens	51-54	
2510664-10	1989	The decline in both SBP and DBP with diltiazem was significantly related to their control values (r = 0.31 and 0.28 respectively, p less than 0.0001 for both).	Diltiazem	37-46	D-box binding PAR bZIP transcription factor	Homo sapiens	28-31	
1884720-8	1991	In the diltiazem group, supine BP was reduced by 10 (11)/10 (6) mmHg (SBP/DBP) at the highest dose level, and the corresponding values for the metoprolol group were 7 (16)/8 (9) mmHg (SBP/DBP).	Diltiazem	7-16	D-box binding PAR bZIP transcription factor	Homo sapiens	74-77	
1884720-8	1991	In the diltiazem group, supine BP was reduced by 10 (11)/10 (6) mmHg (SBP/DBP) at the highest dose level, and the corresponding values for the metoprolol group were 7 (16)/8 (9) mmHg (SBP/DBP).	Diltiazem	7-16	D-box binding PAR bZIP transcription factor	Homo sapiens	188-191	
2283645-6	1990	Moreover, BP control (sitting DBP less than 90 mmHg) was achieved in a greater proportion of patients treated with diltiazem (63 vs 44%).	Diltiazem	115-124	D-box binding PAR bZIP transcription factor	Homo sapiens	30-33	
1706010-7	1990	Sustained-release diltiazem is effective as monotherapy at single daily doses of 300 mg as evidenced by an effect/dose study in 105 patients: DBP = -17 mm Hg with 300 mg (72% of the patients responded to this dosage).	Diltiazem	18-27	D-box binding PAR bZIP transcription factor	Homo sapiens	142-145	
1706014-3	1990	In the groups treated with diltiazem, enalapril, or the combination of both, the drop in arterial blood pressure was 20, 11, and 19 mm Hg for supine diastolic blood pressure (supine DBP): 18, 12, and 19 mm Hg for standing diastolic blood pressure (standing DBP); 22, 20, and 23 mm Hg for supine systolic blood pressure (supine SBP); and 21, 19, and 24 mm Hg for standing systolic blood pressure (standing SBP), respectively.	Diltiazem	27-36	D-box binding PAR bZIP transcription factor	Homo sapiens	182-185	
1706014-3	1990	In the groups treated with diltiazem, enalapril, or the combination of both, the drop in arterial blood pressure was 20, 11, and 19 mm Hg for supine diastolic blood pressure (supine DBP): 18, 12, and 19 mm Hg for standing diastolic blood pressure (standing DBP); 22, 20, and 23 mm Hg for supine systolic blood pressure (supine SBP); and 21, 19, and 24 mm Hg for standing systolic blood pressure (standing SBP), respectively.	Diltiazem	27-36	D-box binding PAR bZIP transcription factor	Homo sapiens	257-260	
1706014-4	1990	The reduction in DBP was significantly more pronounced in the group treated with sustained-release diltiazem 300 mg than in the group treated with enalapril 20 mg. Cardiac tolerance was good for patients treated with sustained-release diltiazem 300 mg alone or the combination therapy: no orthostatic hypotension or lengthening of the PR interval in the electrocardiogram was observed.	Diltiazem	99-108	D-box binding PAR bZIP transcription factor	Homo sapiens	17-20	
1706014-4	1990	The reduction in DBP was significantly more pronounced in the group treated with sustained-release diltiazem 300 mg than in the group treated with enalapril 20 mg. Cardiac tolerance was good for patients treated with sustained-release diltiazem 300 mg alone or the combination therapy: no orthostatic hypotension or lengthening of the PR interval in the electrocardiogram was observed.	Diltiazem	235-244	D-box binding PAR bZIP transcription factor	Homo sapiens	17-20	
1706015-9	1990	Moreover, on day 90, blood pressure values were maintained in the diuretic-treated group, whereas an additional significant reduction in supine DBP (p less than 0.002) was noted in the sustained-release diltiazem 300 mg-treated group (-4.8 mm Hg).	Diltiazem	203-212	D-box binding PAR bZIP transcription factor	Homo sapiens	144-147